REG - JP Morgan Sec LLC Xeris Pharmaceutical - Xeris Pharmaceuticals, Inc 8.3

Xeris Biopharma HoldingsAnnouncement

12/08/2021 14:25

RNS Number : 4932I
  
J.P. Morgan Securities LLC
  
12 August 2021
  
 

Ap19
 
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


J.P. Morgan Securities LLC




Company dealt in


Xeris Pharmaceuticals, Inc.




Class of relevant security to which the dealings being disclosed relate (Note 2)


$0.001 common stock




Date of dealing


11 August 2021




 
2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


3,795,361                5.71


140,597             0.21




(2) Derivatives (other than options)


124,443                0.19


 




(3) Options and agreements to purchase/sell


0


 




Total


3,919,804             5.90


140,597             0.21



 
 
 
 
 
 
 




 

 
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




 
Purchase/sale


 
Number of relevant securities


 
Price per unit (USD)
 
(Note 5)




Purchase(New Borrow)
 
Purchases
Purchases
 
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales


376,400
 
3 
 3 
 
 100 
 3,685 
 600 
 2,000 
 700 
 500 
 2,800 
 400 
 1,877 
 400 
 3,000 
 500 
 300 
 6,759 
 1,687 
 600 
 1,500 
 146 
 7,776 
 6,800 
 522 
 1,600 
 5,900 
 8,100 
 300 
 4,900 
 3,039 
 3


N/A
 
2.3350          USD
2.3500          USD
                        
2.2800          USD
2.2896          USD
2.2900          USD
2.2925          USD
2.2950          USD
2.2960          USD
2.2968          USD
2.2975          USD
2.3000          USD
2.3025          USD
2.3050          USD
2.3060          USD
2.3067          USD
2.3084          USD
2.3100          USD
2.3117          USD
2.3130          USD
2.3132          USD
2.3150          USD
2.3159          USD
2.3200          USD
2.3225          USD
2.3250          USD
2.3253          USD
2.3300          USD
2.3332          USD
2.3350          USD
2.3500          USD




 
 
 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(USD) (Note 5)




 


 


 


 




 
 
 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 




 
                          
 
Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 
     None
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


 12 August 2021




Contact name


Alwyn Basch




Telephone number


0207 742 7407




If a connected EFM, name of offeree/offeror with which connected


N/A




If a connected EFM, state nature of connection (Note 10)


N/A




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ISEZZGMRFZZGMZM